Bausch & Lomb Analyst Ratings
Bausch & Lomb Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
10/13/2023 | 10.05% | Morgan Stanley | $20 → $18.5 | Maintains | Equal-Weight |
10/06/2023 | 24.92% | HC Wainwright & Co. | $22 → $21 | Reiterates | Buy → Buy |
10/03/2023 | 18.97% | Evercore ISI Group | → $20 | Reinstates | → Outperform |
08/04/2023 | 30.87% | HC Wainwright & Co. | → $22 | Reiterates | Buy → Buy |
08/03/2023 | 18.97% | Morgan Stanley | $20 → $20 | Reiterates | Equal-Weight → Equal-Weight |
08/03/2023 | 13.02% | Barclays | $18 → $19 | Maintains | Equal-Weight |
07/24/2023 | 24.92% | RBC Capital | $20 → $21 | Maintains | Outperform |
07/10/2023 | 36.82% | Citigroup | $22 → $23 | Maintains | Buy |
07/03/2023 | 36.82% | B of A Securities | $19 → $23 | Maintains | Buy |
07/03/2023 | 30.87% | HC Wainwright & Co. | → $22 | Reiterates | Buy → Buy |
05/30/2023 | 18.97% | Morgan Stanley | → $20 | Assumes | → Equal-Weight |
05/19/2023 | 30.87% | HC Wainwright & Co. | $19 → $22 | Maintains | Buy |
05/05/2023 | 13.02% | HC Wainwright & Co. | $21 → $19 | Maintains | Buy |
05/05/2023 | 7.08% | Barclays | $17 → $18 | Maintains | Equal-Weight |
05/04/2023 | 18.97% | RBC Capital | → $20 | Reiterates | → Outperform |
03/23/2023 | 24.92% | HC Wainwright & Co. | → $21 | Reiterates | → Buy |
03/09/2023 | — | Needham | Initiates Coverage On | → Hold | |
02/24/2023 | 24.92% | HC Wainwright & Co. | $20 → $21 | Maintains | Buy |
02/23/2023 | 1.13% | JP Morgan | $15 → $17 | Maintains | Neutral |
02/23/2023 | 18.97% | Morgan Stanley | $18 → $20 | Maintains | Equal-Weight |
02/23/2023 | 18.97% | RBC Capital | → $20 | Reiterates | → Outperform |
02/15/2023 | 18.97% | RBC Capital | $17 → $20 | Maintains | Outperform |
02/02/2023 | 18.97% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
12/21/2022 | 1.13% | Barclays | → $17 | Initiates Coverage On | → Equal-Weight |
11/23/2022 | 1.13% | Goldman Sachs | $19 → $17 | Maintains | Neutral |
11/03/2022 | -10.77% | JP Morgan | $16 → $15 | Maintains | Neutral |
11/03/2022 | 1.13% | RBC Capital | $18 → $17 | Maintains | Outperform |
11/03/2022 | 7.08% | Morgan Stanley | $19 → $18 | Maintains | Equal-Weight |
11/03/2022 | 18.97% | HC Wainwright & Co. | $21 → $20 | Maintains | Buy |
10/11/2022 | 13.02% | Morgan Stanley | $20 → $19 | Maintains | Equal-Weight |
09/12/2022 | 24.92% | HC Wainwright & Co. | → $21 | Initiates Coverage On | → Buy |
08/16/2022 | 13.02% | Goldman Sachs | $22 → $19 | Maintains | Neutral |
07/26/2022 | 30.87% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
06/24/2022 | 24.92% | Evercore ISI Group | → $21 | Initiates Coverage On | → Outperform |
06/09/2022 | 18.97% | Morgan Stanley | $22 → $20 | Maintains | Equal-Weight |
06/06/2022 | 30.87% | Citigroup | → $22 | Initiates Coverage On | → Buy |
05/31/2022 | 30.87% | Morgan Stanley | → $22 | Initiates Coverage On | → Equal-Weight |
05/31/2022 | 30.87% | Goldman Sachs | → $22 | Initiates Coverage On | → Neutral |
05/31/2022 | 42.77% | Guggenheim | → $24 | Initiates Coverage On | → Buy |
05/31/2022 | 36.82% | Wells Fargo | → $23 | Initiates Coverage On | → Overweight |
05/11/2022 | 108.2% | Cowen & Co. | → $35 | Initiates Coverage On | → Outperform |
日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
---|---|---|---|---|---|
2023年10月13日 | 10.05% | 摩根士丹利 | $20→$18.5 | 維護 | 等重 |
10/06/2023 | 24.92% | HC Wainwright公司 | $22→$21 | 重申 | 購買→購買 |
10/03/2023 | 18.97% | Evercore ISI集團 | →$20 | 恢復 | →跑贏大盤 |
08/04/2023 | 30.87% | HC Wainwright公司 | →$22 | 重申 | 購買→購買 |
08/03/2023 | 18.97% | 摩根士丹利 | $20→$20 | 重申 | 等重→等重 |
08/03/2023 | 13.02% | 巴克萊 | $18→$19 | 維護 | 等重 |
07/24/2023 | 24.92% | 加拿大皇家銀行資本 | $20→$21 | 維護 | 跑贏大盤 |
07/10/2023 | 36.82% | 花旗集團 | $22→$23 | 維護 | 買 |
07/03/2023 | 36.82% | B of A證券 | $19→$23 | 維護 | 買 |
07/03/2023 | 30.87% | HC Wainwright公司 | →$22 | 重申 | 購買→購買 |
2023年05月30日 | 18.97% | 摩根士丹利 | →$20 | 假設 | →等重 |
2023年05月19日 | 30.87% | HC Wainwright公司 | $19→$22 | 維護 | 買 |
05/05/2023 | 13.02% | HC Wainwright公司 | $21→$19 | 維護 | 買 |
05/05/2023 | 7.08% | 巴克萊 | $17→$18 | 維護 | 等重 |
05/04/2023 | 18.97% | 加拿大皇家銀行資本 | →$20 | 重申 | →跑贏大盤 |
03/23/2023 | 24.92% | HC Wainwright公司 | →$21 | 重申 | →購買 |
03/09/2023 | - | 李約瑟 | 開始承保 | →保留 | |
02/24/2023 | 24.92% | HC Wainwright公司 | $20→$21 | 維護 | 買 |
02/23/2023 | 1.13% | 摩根大通 | $15→$17 | 維護 | 中性 |
02/23/2023 | 18.97% | 摩根士丹利 | $18→$20 | 維護 | 等重 |
02/23/2023 | 18.97% | 加拿大皇家銀行資本 | →$20 | 重申 | →跑贏大盤 |
02/15/2023 | 18.97% | 加拿大皇家銀行資本 | $17→$20 | 維護 | 跑贏大盤 |
02/02/2023 | 18.97% | HC Wainwright公司 | →$20 | 重申 | →購買 |
2022年12月21日 | 1.13% | 巴克萊 | →$17 | 開始承保 | →等重 |
2022年11月23日 | 1.13% | 高盛 | $19→$17 | 維護 | 中性 |
11/03/2022 | -10.77% | 摩根大通 | $16→$15 | 維護 | 中性 |
11/03/2022 | 1.13% | 加拿大皇家銀行資本 | $18→$17 | 維護 | 跑贏大盤 |
11/03/2022 | 7.08% | 摩根士丹利 | $19→$18 | 維護 | 等重 |
11/03/2022 | 18.97% | HC Wainwright公司 | $21→$20 | 維護 | 買 |
2022年10月11日 | 13.02% | 摩根士丹利 | $20→$19 | 維護 | 等重 |
09/12/2022 | 24.92% | HC Wainwright公司 | →$21 | 開始承保 | →購買 |
08/16/2022 | 13.02% | 高盛 | $22→$19 | 維護 | 中性 |
07/26/2022 | 30.87% | 加拿大皇家銀行資本 | →$22 | 開始承保 | →跑贏大盤 |
2022/06/24 | 24.92% | Evercore ISI集團 | →$21 | 開始承保 | →跑贏大盤 |
06/09/2022 | 18.97% | 摩根士丹利 | $22→$20 | 維護 | 等重 |
06/06/2022 | 30.87% | 花旗集團 | →$22 | 開始承保 | →購買 |
2022年05月31日 | 30.87% | 摩根士丹利 | →$22 | 開始承保 | →等重 |
2022年05月31日 | 30.87% | 高盛 | →$22 | 開始承保 | →中性 |
2022年05月31日 | 42.77% | 古根海姆 | →$24 | 開始承保 | →購買 |
2022年05月31日 | 36.82% | 富國銀行 | →$23 | 開始承保 | →超重 |
2022年05月11日 | 108.2% | 考恩公司 | →$35 | 開始承保 | →跑贏大盤 |
What is the target price for Bausch & Lomb (BLCO)?
博士倫的目標價是多少?
The latest price target for Bausch & Lomb (NYSE: BLCO) was reported by Morgan Stanley on October 13, 2023. The analyst firm set a price target for $18.50 expecting BLCO to rise to within 12 months (a possible 10.05% upside). 29 analyst firms have reported ratings in the last year.
博士倫(紐約證券交易所代碼:BLCO)的最新目標價是由摩根士丹利於2023年10月13日報道的。這家分析公司將目標價定為18.50美元,預計BLCO將在12個月內上漲(可能上漲10.05%)。去年有29家分析公司公佈了評級。
What is the most recent analyst rating for Bausch & Lomb (BLCO)?
博士倫(Bausch&Lomb)最近的分析師評級是多少?
The latest analyst rating for Bausch & Lomb (NYSE: BLCO) was provided by Morgan Stanley, and Bausch & Lomb maintained their equal-weight rating.
博士倫(紐約證券交易所代碼:BLCO)的最新分析師評級由摩根士丹利提供,博士倫維持其同等權重評級。
When is the next analyst rating going to be posted or updated for Bausch & Lomb (BLCO)?
博士倫(Bausch&Lomb)的下一次分析師評級何時發佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bausch & Lomb, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bausch & Lomb was filed on October 13, 2023 so you should expect the next rating to be made available sometime around October 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括查看公開的財務報表,與博士倫的高管和客戶交談,以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。博士倫的上一次評級是在2023年10月13日提交的,因此你應該預計下一次評級將在2024年10月13日左右的某個時候公佈。
Is the Analyst Rating Bausch & Lomb (BLCO) correct?
分析師對博士倫的評級正確嗎?
While ratings are subjective and will change, the latest Bausch & Lomb (BLCO) rating was a maintained with a price target of $20.00 to $18.50. The current price Bausch & Lomb (BLCO) is trading at is $16.81, which is out of the analyst's predicted range.
雖然評級是主觀的,並將發生變化,但博士倫(BLCO)的最新評級維持不變,目標價在20.00美元至18.50美元之間。博士倫目前的股價為16.81美元,超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。